Position ahead of summer 2026 data readout, which could validate NBD1 stabilization as a new mechanism in CF. Monitor for signs of clinical differentiation, especially in sweat chloride reduction beyond Trikafta alone. Given recent insider selling of $50.8M, assess management conviction at data release.
SION drugs
SION drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $39.21entry
- T+1 · 7mo ago +0.97%α +1.45% · $39.59
- T+5 · 7mo ago +3.16%α +2.76% · $40.45
- T+20 · 6mo ago +9.36%α +4.40% · $42.88
- T+60 · 4mo ago +14.84%α +10.07% · $45.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sionna Therapeutics announced completion of patient enrollment in its Phase 2a PreciSION CF trial evaluating SION-719, a first-in-class NBD1 stabilizer, in cystic fibrosis patients on Trikafta. Topline data is expected in summer 2026, marking a key clinical catalyst for the company's novel CFTR-targeting approach.
Key Facts
- Completed enrollment in Phase 2a PreciSION CF trial for SION-719, a first-in-class NBD1 stabilizer.
- Trial evaluates SION-719 added to Trikafta in F508del-homozygous CF patients using a crossover design.
- Primary endpoints include safety, pharmacokinetics, and change in sweat chloride levels (a biomarker of CFTR function).
- Topline data expected in summer 2026, representing a near-term clinical readout.
- Trial conducted across sites in the CF Foundation’s Therapeutics Development Network.
Financial Impact
No direct financial impact disclosed; clinical milestone de-risking potential ahead of data readout.
Risk Factors
- Clinical failure risk: No guarantee that SION-719 will show meaningful improvement in sweat chloride or safety.
- High valuation sensitivity: With $1.7B market cap and no approved products, stock is highly dependent on clinical execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281460 |
Track record
22 reports on SION
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers